A randomized trial of the choice of treatment in prostate cancer: design and baseline characteristics

被引:24
作者
Auvinen, A [1 ]
Vornanen, T
Tammela, TLJ
Ala-Opas, M
Leppilahti, M
Salminen, P
Hakama, M
机构
[1] Univ Tampere, Sch Publ Hlth, FIN-33014 Tampere, Finland
[2] Finnish Canc Registry, FIN-00170 Helsinki, Finland
[3] Kymenlaakso Cent Hosp, Dept Surg, Kotka, Finland
[4] Tampere Univ Hosp, Dept Urol, Tampere, Finland
[5] Kuopio Univ Hosp, Dept Urol, SF-70210 Kuopio, Finland
[6] Seinajoki Cent Hosp, Dept Surg, Seinajoki, Finland
[7] Kanta Hame Cent Hosp, Dept Surg, Hameenlinna, Finland
关键词
prostate neoplasms; quality of life; decision making; patient participation; randomised controlled trials;
D O I
10.1046/j.1464-4096.2001.02421.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective To assess the effects of different approaches to decision-making on the treatment chosen for prostate cancer and on the patients' quality of life in prostate cancer, Patients and methods A multicentre randomized trial was conducted. including all histologically confirmed cases of prostate cancer diagnosed between September 1993 and November 1994 in four Finnish hospitals. in the intervention group, the role of the patient in the choice of treatment was actively emphasized. In the control group. the treatment was chosen using standardized treatment protocols. The first intermediate endpoint was the patient's participation in decisionmaking and the next will be the treatment chosen in the intervention and control groups. The main outcome will be the quality of life. Clinical data on prognostic factors including age. tumour grade, stage, functional Status and serum prostate-specific antigen (PSA) concentration was collected for comparison between the arms, and between those enrolled or not. Results In all. 210 of 251 eligible patients were randomized into the two arms. Patients were randomized before obtaining informed consent. which led to four patients already randomized refusing to participate. The 41 patients not enrolled were of similar age and grade distribution. but more frequently had extensive disease than had those enrolled in the trial. Three patients were unable to participate because of rapid deterioration in their general condition after randomization. There were no clear differences in baseline characteristics (including age, functional status. tumour grade and stage) of the patients between the arms. The distribution of PSA level differed slightly between the arms, which may require adjustment in the analyses. Patients in the intervention arm participated in decision-making more actively than those in the control arm. Conclusion Randomized studies on ethical issues such as the patient's role in choosing treatment are feasible and likely to provide important information.
引用
收藏
页码:708 / 715
页数:8
相关论文
共 19 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   Health-related quality of life among patients with metastatic prostate cancer [J].
Albertsen, PC ;
Aaronson, NK ;
Muller, MJ ;
Keller, SD ;
Ware, JE .
UROLOGY, 1997, 49 (02) :207-216
[3]   Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: A prospective multiinstitutional outcomes study [J].
Beard, CJ ;
Propert, KJ ;
Rieker, PP ;
Clark, JA ;
Kaplan, I ;
Kantoff, PW ;
Talcott, JA .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :223-229
[4]   Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30 [J].
Borghede, G ;
Sullivan, M .
QUALITY OF LIFE RESEARCH, 1996, 5 (02) :212-222
[5]   Assessment of quality of life after radical radiotherapy for prostate cancer [J].
Caffo, O ;
Fellin, G ;
Graffer, U ;
Luciani, L .
BRITISH JOURNAL OF UROLOGY, 1996, 78 (04) :557-563
[6]  
CATALONA WJ, 1994, NEW ENGL J MED, V331, P996
[7]   Self-assessed health-related quality of life in men being treated for prostate cancer with radiotherapy: Instrument validation and its relation to patient-assessed bother of symptoms [J].
Dale, W ;
Campbell, T ;
Ignacio, L ;
Song, P ;
Kopnick, M ;
Mamo, C ;
Ray, P ;
Vijayakumar, S .
UROLOGY, 1999, 53 (02) :359-366
[8]  
DASILVA FC, 1993, CANCER, V71, P1138, DOI 10.1002/1097-0142(19930201)71:3+<1138::AID-CNCR2820711436>3.0.CO
[9]  
2-7
[10]   The quality of life of patients with newly diagnosed M1 prostate cancer: Experience with EORTC clinical trial 30853 [J].
daSilva, FC ;
Fossa, SD ;
Aaronson, NK ;
Serbouti, S ;
Denis, L ;
Casselman, J ;
Whelan, P ;
Hetherington, J ;
Fava, C ;
Richards, B ;
Robinson, MRG .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (01) :72-77